In January 2025, the U.S. Food and Drug Administration (FDA) officially approved Datroway (datopotamab deruxtecan), an antibody-drug conjugate (ADC) co-developed by AstraZeneca and Daiichi Sankyo, for the treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-negative advanced breast cancer. This milestone reinforces the growing impact of ADCs in precision oncology, offering a targeted approach to deliver potent cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues.
As a pioneer in next-generation ADC delivery technologies, Litchlab is committed to enhancing the stability, targeting precision, and therapeutic index of ADCs, accelerating their clinical translation and commercialization.
The success of an ADC depends not only on the selection of the antibody and cytotoxic payload but also on the efficiency of its delivery system and conjugation chemistry. Litchlab leverages its cutting-edge lipid nanoparticle (LNP) and polymeric microsphere platforms to provide industry-leading solutions for ADC drug development:
Precision particle size control ensures high conjugation stability, leading to uniform in vivo distribution.
Optimized linker chemistry extends ADC plasma half-life and reduces off-target toxicity for an improved safety profile.
Ligand-functionalized ADCs (antibody-aptamer conjugation) enable superior tumor-specific recognition, increasing ADC accumulation in cancerous tissues.
pH-responsive drug release mechanisms allow for precise payload release within tumor cells, maximizing anticancer activity while reducing systemic exposure.
LNP-based ADC formulations improve payload stability and tumor penetration, enhancing therapeutic outcomes.
Polymeric microsphere-based sustained release reduces premature ADC degradation in circulation and ensures more efficient drug targeting at the tumor site.
Litchlab’s innovative ADC delivery technologies are being applied across multiple therapeutic areas, including:
Precision Oncology: Optimizing tumor-specific ADC targeting to enhance efficacy and reduce toxicity.
Combination Therapies: Supporting ADC + immune checkpoint inhibitors (PD-1/PD-L1) combination strategies to boost immune system responses against tumors.
Early-Stage Clinical Translation: Providing end-to-end support from formulation development to cGMP manufacturing, accelerating ADC candidates toward regulatory approval.
The FDA approval of Datroway marks a significant milestone for ADC therapy, reinforcing its role in the evolution of targeted cancer treatment. Litchlab remains at the forefront of ADC drug delivery, working alongside global biopharma companies to push the boundaries of ADC technology, enhance drug stability, and improve clinical outcomes.
Unlock the full potential of Litchlab’s ADC delivery technology—empowering the next generation of precision cancer therapy.
For more information, please feel free to contact us at:
E-Mail:RD1@Litchlab.com
